There were essentially no hospitalizations or deaths in the Vaccine Group whereas in the Placebo Group there were. This tells us we have a valueadded additional vaccine cand candidate. There are other advantages. It is cheaper, only requires a single shot and only basic refrigeration. No vaccine has yet been authorized in the vaccine for use by anyone under 16 but theres more news. Today, dr. Fauci addressed when that could change and when kids could start to get vaccinated, the new variants of the virus are also causing potential problems as Athena Jones Now rep reports. Reporter another covid19 vaccine could be available in the United States. The results are very encouraging. Reporter Johnson Johnsons vaccine was 66 overall in a phase three trial, 72 effective in the u. S. And 85 effective against severe disease. The drug is delivered in a single shot and does not have to be stored frozen, making distribution ease her. There is real benefit to having a singledose vaccine and one that
started doing people that were younger than 16. you remember their vaccine is for 16 and older. but as you mention, let me show you, this is some of the youngest trial participants that we ve now heard. over 6,000 people age 6 months to 11 years. and then you have 3,000 adolescents, age 12 to 17 years. what s happening now is they re going to trial these, again, very young participants with various doses of the vaccine. 25 micro gram, 50 microgram, 100 mi microgram. they re trying to figure out two things, is this safe in people of that age and what is the right dose to give as well. after that, if those things sort of if they get the information they need and sprois proven safe, they can bridge these trials to existing trials. meaning, hey, we get a lot of information. they could get some results early. as you heard, dr. fauci said by the fall potentially high school students potentially could have a vaccine. i was going to ask you about the timeline there. so if this go
benefits outweighing the risks have to be proven. for all the reasons that dr. miesner is saying. and that may involved more involved safety studies. you know, when they did 12 to 15-year-old authorization, they did more what they call bridging trials. they bridged a lot of the data from older people to that that age group. with younger people, you are going to have to do these safety trials and and more complete data s going to need to be, you know, really accrued here. to to prove that benefit-risk ratio. i think, you know, one of the things i think, you know, is important to remember is that we look at hospitalizations. we look at deaths. but i think, one thing we have learned is that you don t want this virus. you don t want to get infected, because we don t, still, know if some of the longer-term consequences even if people who have had milder illness. that wouldn t be counted towards that severe illness. and and i am curious, along those lines, dr. miesner, when you look
medical correspondent, sanjay gupta. based on what you know, where do you stand on the issue? you know, i want to be very careful here. i think the doctor would agree we don t want to be empowering increased vaccine hesitancy here, which is always a potential consequence. no question that for an authorization, emergency authorization, the ratio of benefits outweighing the risks have to be proven for all the reasons that the doctor is saying. that may involve more involved safety studies. whe when they did 12 to 15 authorization, they did more bridging trials. they bridged a lot of the data from older people to that age group. with younger people, you have to do the safety trials and more complete data needs to be accrued to prove that. one of the things i think is
Coronavirus News LIVE Updates: Hours after Modi's announcement to cancel class 12 exams, the Karnataka government said it will too take a call on whether to conduct SSLC and II PU exams.